Combined Letrozole and Growth Hormone Therapy in Late-Pubertal Males with Advanced Bone Age and Open Knee Physes
Children · 14.08.2026 · 13 (8) · 1077
DOI: 10.3390/children13081077 ↗Kurz gefasst
Fachartikel in der Zeitschrift Children, online erschienen am 14.08.2026. Verfasst von Hui Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Peking University Third Hospital, Beijing 100191, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Peking University Third Hospital, Beijing Integrative Medicine Association, National Institute of Hospital Administration, National Health Commission of China.
Abstract (Originalsprache)
Background/Objectives: The therapeutic window for growth hormone (GH) therapy in late-pubertal males with advanced bone age (BA ≥ 15 years) is generally considered closed. Yet, open knee physes may indicate residual growth potential. This single-arm retrospective study evaluated the efficacy and safety of letrozole combined with GH in Chinese males with short stature, advanced BA (15 –< 18 years), and open knee physes.
Methods
We included 139 male adolescents stratified by baseline BA: 15 ≤ BA < 16 (n = 24), 16 ≤ BA < 17 (n = 31), and 17 ≤ BA < 18 (n = 84). All received subcutaneous GH (0.05–0.07 mg/kg/day) and oral letrozole (2.5 mg/day). The primary outcome was the change in final adult height (FAH) from baseline predicted adult height (PAH). Longitudinal changes in height velocity and height SDS-BA were also assessed.
Results
Among 75 patients who reached FAH, combination therapy was associated with a mean gain of 6.58 ± 3.46 cm over baseline PAH (p < 0.001). The gain was inversely correlated with baseline BA; the largest gain occurred in the 15 ≤ BA < 16 subgroup (10.04 ± 4.66 cm), significantly exceeding gains in the 16 ≤ BA < 17 (6.30 ± 3.01 cm) and 17 ≤ BA < 18 (5.70 ± 2.52 cm) subgroups (p < 0.001). In the youngest subgroup, FAH exceeded mid-parental height. The safety profile was acceptable; acne was the most common adverse event (46.76%), and no severe metabolic or endocrine disorders were observed.
Conclusions
Letrozole plus GH therapy may be associated with improved FAH in late-pubertal males with advanced BA and open knee physes, with gains varying by baseline skeletal maturity and being numerically greatest in those with BA 15 –< 16 years. Knee epiphyseal status may be a useful consideration when individualizing therapy in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Peking University Third Hospital, Beijing 100191, China.
- Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
- Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China.
- Clinical Epidemiology Research Center, Peking University Third Hospital, Beijing 100191, China.
ORCID-Profile: Pengxiang Zhou
Förderung
- Peking University Third Hospital
- Beijing Integrative Medicine Association
- National Institute of Hospital Administration, National Health Commission of China
Zitieren
APA
Zhang, H., Zhou, P., Cui, Y., Wang, X., Liu, H., Yuan, J., Zhang, H., Zhao, R., Han, T., & Wang, X. (2026). Combined Letrozole and Growth Hormone Therapy in Late-Pubertal Males with Advanced Bone Age and Open Knee Physes. Children, 13(8), 1077. https://doi.org/10.3390/children13081077
Vancouver
Zhang H, Zhou P, Cui Y, Wang X, Liu H, Yuan J, et al. Combined Letrozole and Growth Hormone Therapy in Late-Pubertal Males with Advanced Bone Age and Open Knee Physes. Children. 2026;13(8):1077. doi:10.3390/children13081077
BibTeX
@article{Zhang2026,
author = {Zhang, Hui and Zhou, Pengxiang and Cui, Yunpu and Wang, Xuemei and Liu, Huiqiang and Yuan, Jinfang and Zhang, Hua and Zhao, Rongsheng and Han, Tongyan and Wang, Xinli},
title = {Combined Letrozole and Growth Hormone Therapy in Late-Pubertal Males with Advanced Bone Age and Open Knee Physes},
journal = {Children},
year = {2026},
volume = {13},
number = {8},
pages = {1077},
doi = {10.3390/children13081077}
}
EUVIMED